吉林大学学报(医学版) ›› 2025, Vol. 51 ›› Issue (2): 378-391.doi: 10.13481/j.1671-587X.20250212

• 基础研究 • 上一篇    

蛋白激酶 D2在膀胱癌组织中的表达及其对肿瘤免疫微环境的影响

蔡文畅1,2,刘雨齐1,3,王涵1,3,王鹤霖3,王振江3,肖梓屾3,马士远3,安丽萍1,刘艳波1,3()   

  1. 1.北华大学长白山药用动植物活性多肽研究与开发国家地方联合工程实验室,吉林 吉林 132013
    2.北华大学校医院检验科,吉林 吉林 132013
    3.北华大学基础医学院病理生理学教研室,吉林 吉林 132013
  • 收稿日期:2024-06-14 接受日期:2024-07-12 出版日期:2025-03-28 发布日期:2025-04-22
  • 通讯作者: 刘艳波 E-mail:liuyanbobeihua@163.com
  • 作者简介:蔡文畅(1973-),女,吉林省松原市人,主管检验师,主要从事泌尿生殖系统恶性肿瘤发病机制方面的研究。
  • 基金资助:
    吉林省科技厅国际合作项目(20210402015GH);吉林省科技厅基础研究项目(YDZJ202201ZYTS194);北华大学研究生创新项目(研创合字2024021)

Expression of protein kinase D2 in bladder cancer tissue and its effect on tumor immune microenvironment

Wenchang CAI1,2,Yuqi LIU1,3,Han WANG1,3,Helin WANG3,Zhenjiang WANG3,Zishen XIAO3,Shiyuan MA3,Liping AN1,Yanbo LIU1,3()   

  1. 1.National and Local United Engineering R&D Center of Research and Development on Active Peptide of Medicinal Plants and Animals in ChangBai Mountains,Beihua University,Jilin 132013,China
    2.Clinical Laboratory,School Hospital,Beihua University,Jilin 132013,China
    3.Department of Pathophysiology,School of Basic Medical Sciences,Beihua University,Jilin 132013,China
  • Received:2024-06-14 Accepted:2024-07-12 Online:2025-03-28 Published:2025-04-22
  • Contact: Yanbo LIU E-mail:liuyanbobeihua@163.com

摘要:

目的 利用生物信息学技术探讨蛋白激酶D2(PRKD2)在膀胱癌(BLCA)组织中的表达及其表达对BLCA患者预后的影响,阐明PRKD2在BLCA发生发展中的作用。 方法 从UCSC癌症基因组数据库下载9例正常膀胱样本、19例BLCA癌旁样本和407例BLCA肿瘤样本的数据。采用Mann-Whitney U检验分析PRKD2 mRNA在BLCA肿瘤组织与正常膀胱组织中的表达差异,并利用人类蛋白数据库(HPA)进行蛋白组学的验证。使用R软件的DESeq2包对PRKD2低表达组和PRKD2高表达组BLCA样本进行差异表达基因(DEGs)筛选及鉴定,使用ggplot2包绘制PRKD2的共表达热图,利用基因本体(GO)功能注释和京都基因与基因组百科全书(KEGG)对DEGs进行GO功能注释及KEGG信号通路富集分析,并使用基因富集分析(GSEA)获得DEGs明显富集的基因集。根据PRKD2的表达水平将BLCA样本分为低表达组和高表达组,使用GSVA包分析BLCA患者PRKD2表达与免疫细胞浸润之间相关性。使用survival包和survminer包进一步分析PRKD2与BLCA患者预后的关系。使用cBioPortal数据库对BLCA组织的PRKD2基因突变情况进行分析。收集膀胱炎、膀胱息肉和BLCA组织,使用免疫组织化学染色技术检测BLCA及对照组织中白细胞介素17F(IL-17F)蛋白表达水平。 结果 PRKD2在多种恶性肿瘤组织中高表达,BLCA组织中PRKD2 mRNA和蛋白表达水平较正常膀胱组织明显升高(P<0.05)。对PRKD2单基因差异分析共得到1 058个DEGs,其中上调DEGs 29个,下调DEGs 1 029个。GO功能注释和KEGG信号通路富集分析,DEGs主要富集于涉及感官知觉的化学刺激、卡哈尔体和内肽酶抑制剂活性等生物学过程(BP)以及金黄色葡萄球菌感染通路和年轻人的成熟型糖尿病通路。GSEA分析,DEGs主要富集于Notch 信号通路、维甲酸诱导基因I(RIG-I)样受体信号通路、胞质DNA筛选通路、碱基切除修复信号通路、自然杀伤(NK)细胞介导细胞毒性信号通路和T细胞受体信号通路等过程。免疫浸润分析,PRKD2的表达与活化的树突状细胞(aDC)、NK细胞中的CD56dim亚群(NK CD56dim cells)和中央记忆型T细胞(Tcm)等5种细胞呈正相关关系(P<0.05),与巨噬细胞、效应记忆T细胞(Tem)和浆细胞样树突状细胞(pDC)呈负相关关系(P<0.05)。临床特征亚组分析,年龄超过70岁以及发生淋巴管侵袭的BLCA患者PRKD2 mRNA表达水平明显降低(P<0.05),PRKD2 mRNA表达水平较高的BLCA患者总生存期(OS)、疾病特异性生存期(DSS)和无进展间隔期(PFI)明显长于PRKD2 mRNA表达水平较低者(P<0.05)。单因素和多因素Cox回归分析,发生远处转移、主要治疗结果和临床病理分期是影响BLCA患者预后的重要因素。基因突变分析,9%的患者出现PRKD2基因突变,包括错义突变、基因扩增、mRNA低表达、mRNA高表达以及多位点突变。免疫组织化学法,与膀胱炎组织比较,BLCA组织中IL-17F蛋白表达水平明显升高(P<0.05)。 结论 BLCA组织中PRKD2表达水平明显升高,PRKD2具有上调IL-17F蛋白表达水平的效应,PRKD2蛋白表达水平降低可能是BLCA患者预后不良的潜在因素。

关键词: 膀胱肿瘤, 蛋白激酶D2, 肿瘤免疫微环境, 预后标志物, 生物信息学分析

Abstract:

Objective To investigate the expression of protein kinase D2 (PRKD2) in bladder cancer (BLCA) tissue using bioinformatics analysis method and its effect on the prognosis of BLCA patients, and to clarify the role of PRKD2 in the occurrence and development of BLCA. Methods The data from 9 normal bladder samples, 19 BLCA paracancerous samples, and 407 BLCA tumor samples were downloaded from the UCSC Cancer Genome Database. The Mann-Whitney U test was applied to analyze the difference in expression of PRKD2 mRNA in BLCA tumor and normal bladder tissues, and the Human Protein Atlas (HPA) database was used for proteomic validation. DESeq2 package in R software was applied to screen the differentially expressed genes (DEGs) in BLCA tissue in PRKD2 low- and high-expression groups. The co-expression heatmaps of PRKD2 were plotted using the ggplot2 package, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were used for functional annotation analysis and pathway enrichment analysis of DEGs, and Gene Set Enrichment Analysis (GSEA) was used to obtain the gene sets that were significantly enriched for DEGs. The BLCA samples were divided into low- and high-expression groups according to the expression level of PRKD2, and the correlations between PRKD2 expression and immune cell infiltration in the BLCA patients were analyzed with GSVA package. The relationship between PRKD2 and prognosis of BLCA patients was further analyzed using the survival package and the survminer package. The PRKD2 gene mutations in BLCA tissue were analyzed using the cBioPortal database. The cystitis, bladder polyp and BLCA tissues were collected, and the expression levels of interleukin-17F (IL-17F) protein in BLCA and control tissues were detected using immunohistochemical staining technique. Results PRKD2 was highly expressed in a variety of malignant tumors, and the expression levels of PRKD2 mRNA and protein in BLCA tissue were significantly increased compared with those in normal bladder tissue (P<0.05). Single gene differential analysis of PRKD2 yielded a total of 1 058 DEGs, of which a total of 29 genes were up-regulated and 1 029 were down-regulated. The results of GO functional enrichment analysis showed that DEGs were mainly enriched in the biological process (BP), such as chemical stimuli involved in sensory perception, Cajal body, and endopeptidase inhibitor activity. The results of KEGG pathway analysis showed that DEGs were mainly enriched in the pathway of Staphylococcus aureus infection and the pathway of maturity onset diabetes of the young. GSEA analysis showed that DEGs were mainly enriched in the Notch signaling pathway, the retinoic acid-inducible gene-Ⅰ(RIG-Ⅰ)-like receptor signaling pathway, the cytoplasmic DNA screening pathway, the base excision repair signaling pathway, natural killer (NK) cell-mediated cytotoxicity signaling pathway and T cell receptor signaling pathway. The results of immune infiltration analysis indicated that the expression of PRKD2 was positively correlated with five types of cells, such as activated dendritic cells (aDC), NK CD56dim cells and central memory T cells (Tcm) (P<0.05), and negatively correlated with three types of immune cells, including macrophages, effector memory T cells (Tem) and plasmacytoid dendritic cells (pDC) (P<0.05).The clinical characteristic subgroup analysis results showed that the expression levels of PRKD2 mRNA in BLCA patients who were over 70 years old and developed lymphovascular invasion were decreased (P<0.05); the overall survival (OS), disease-specific survival (DSS) and progression-free interval (PFI) in the BLCA patients with PRKD2 high expression were significantly longer than those with PRKD2 low expression (P<0.05). The univariate and multivariate Cox analyses indicated that distant metastasis, primary therapy outcome and clinicopathologic stage were the important factors affecting BLCA prognosis. About 9% patients had PRKD2 gene mutations, including missense mutation, gene amplification, mRNA low or high expression, and multi-motif mutation. The immunohistochemistry results showed that the expression level of IL-17F protein in BLCA tissue was significantly higher than that in cystitis tissue (P<0.05). Conclusion The expression level of PRKD2 in BLCA tissue is obviously increased, which could up-regulate the expression of IL-17F protein, and the decrease of PRKD2 protein expression may be a potential factor for the poor prognosis of BLCA patients.

Key words: Bladder neoplasm, Protein kinase D2, Tumor immune microenvironment, Prognostic marker, Bioinformatics analysis

中图分类号: 

  • R737